Research and Markets: The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/85ad83/the_neurodiagnosti) has announced the addition of the "The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics" report to their offering.

“The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics”

Fully updated second annual industry insider report detailing markets and emerging diagnostics in neurology and psychiatry.

Nearly 2 billion people worldwide and 100 million people in the US are affected by a brain or nervous system disorder including addiction, Alzheimers disease, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinsons disease, sensory disorders, and sleep disorders. Diagnosis of these disorders is rapidly changing as new tools are developed for more objective and personalized assessment and treatment.

In addition to the massive unmet markets, long-term growth in neurodiagnostics is being driven by technology advances and equipment upgrades in neuroimaging; new biomarkers and imaging protocols for early diagnosis and disease monitoring; and increased use of imaging and informatics in drug and device development.

NeuroInsights has identified three primary markets in neurodiagnostics which are discussed in detail in this report:

• Neuroimaging: Medical equipment and reagents for research, diagnostics and patient monitoring, including MRI, CT, PET, SPECT, EEG and MEG.
• In vitro diagnostics: Genetic testing, biomarker assays and chemical profiling of human samples, including urine, blood, cerebral spinal fluid and tissue.
• Neuroinformatics: Multidimensional databases and software systems that store and analyze data from the genetic to the behavioral level.

Key Topics Covered:

1 Neurodiagnostic Markets

• Neurodiagnostics Industry Taxonomy
• FDA Approval and Reimbursement of Diagnostics
• Market Opportunities in Neurology and Psychiatry
• Number of People impacted by Neurological and Psychiatric Disorders, WW and US
• Neurology Markets and Emerging Diagnostics
• Diagnostic Tests for Alzheimers on the Horizon
• Psychiatry Markets and Emerging Diagnostics

2 Neuroimaging

• Computed Tomography (CT)
• Nuclear Medicine Imaging (PET, SPECT)
• Electro-encephalography (EEG)
• Magneto-encephalography (MEG)

3 In Vitro Diagnostics

• In Vitro Diagnostics Regulatory Landscape
• Genetic Testing and Pharmacogenomics
• Protein Biomarker Assays
• Pattern Recognition in Diagnostics

4 Neuroinformatics

• Neuroinformatics Databases
• Paul Allen Brain Atlas Project
• IBM Blue Brain Project
• Diagnostic Software

5 Investing in Neurodiagnostics

• Venture Capital Investment
• Neurodiagnostic Venture Financings, Companies and Investors 2005-2009
• Public Investment Activity and IPOs
• Diagnostic Initial Public Offerings (IPOs) 2004 - 2009
• Public Neurodiagnostic Related Companies, Stock Performance and Fundamentals
• Merger and Acquisition Activity

6 Company Profiles

• Neurodiagnostic Companies: Private
• Neurodiagnostic Companies: Public

Partial list of companies include:

• Abbot Diagnostics
• Adlyfe
• Advanced Brain Monitoring
• Aspect Medical (Covidien)
• Athena Diagnostics
• Avid Radiopharmaceuticals
• BioBehavioral Diagnostics
• Brain Resource
• BrainScope
• Cambridge Cognition
• CNS Response
• Cytox
• Electrical Geodesics
• ExonHit
• GE Healthcare
• GeneNews
• g-Nostics
• Johnson & Johnson
• Kappametrics
• Natus Medical
• NeuroMetrix
• NeuroVigil
• NeuroVista
• NeuroTrax
• Orasi Medical
• Philips Healthcare
• Quest Diagnostics
• Rules-Based Medicine
• Satoris and more.

To view the full list of 150 companies included in this extensive report, please click the link below

For more information visit http://www.researchandmarkets.com/research/85ad83/the_neurodiagnosti

Source: NeuroInsights